DE60212424D1 - Radiopharmazeutishes mittel zur behandlung von krebs im frühstadium - Google Patents

Radiopharmazeutishes mittel zur behandlung von krebs im frühstadium

Info

Publication number
DE60212424D1
DE60212424D1 DE60212424T DE60212424T DE60212424D1 DE 60212424 D1 DE60212424 D1 DE 60212424D1 DE 60212424 T DE60212424 T DE 60212424T DE 60212424 T DE60212424 T DE 60212424T DE 60212424 D1 DE60212424 D1 DE 60212424D1
Authority
DE
Germany
Prior art keywords
treatment
radiopharmaceutic
cancer
agent
stadium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60212424T
Other languages
English (en)
Other versions
DE60212424T2 (de
Inventor
E Kiefer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dow Global Technologies LLC
Original Assignee
Dow Global Technologies LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dow Global Technologies LLC filed Critical Dow Global Technologies LLC
Publication of DE60212424D1 publication Critical patent/DE60212424D1/de
Application granted granted Critical
Publication of DE60212424T2 publication Critical patent/DE60212424T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/0002General or multifunctional contrast agents, e.g. chelated agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0474Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0497Organic compounds conjugates with a carrier being an organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6524Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having four or more nitrogen atoms as the only ring hetero atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60212424T 2001-10-22 2002-10-22 Radiopharmazeutisches mittel zur behandlung von krebs im frühstadium Expired - Fee Related DE60212424T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35559801P 2001-10-22 2001-10-22
US355598P 2001-10-22
PCT/US2002/033918 WO2003035114A1 (en) 2001-10-22 2002-10-22 Radiopharmaceutical agent for the treatment of early stage cancer

Publications (2)

Publication Number Publication Date
DE60212424D1 true DE60212424D1 (de) 2006-07-27
DE60212424T2 DE60212424T2 (de) 2006-10-12

Family

ID=23398047

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60212424T Expired - Fee Related DE60212424T2 (de) 2001-10-22 2002-10-22 Radiopharmazeutisches mittel zur behandlung von krebs im frühstadium

Country Status (6)

Country Link
US (1) US20030133872A1 (de)
EP (1) EP1438076B1 (de)
JP (1) JP2005507001A (de)
AT (1) ATE329623T1 (de)
DE (1) DE60212424T2 (de)
WO (1) WO2003035114A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005049096A2 (en) * 2003-11-14 2005-06-02 Dow Global Technologies Inc. Protein and polymer conjugates as chelants with enhanced blood retention
EP1778699A4 (de) * 2004-08-10 2009-02-25 Dow Global Technologies Inc Targeting von chelanten und chelaten
MX2018000239A (es) * 2015-07-07 2018-05-23 Five Eleven Pharma Inc Bifosfonatos de hbed, sus conjugados radio metalicos y su uso como agentes teranosticos.

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3994996A (en) * 1972-02-11 1976-11-30 Fmc Corporation Polymeric phosphazenes and process for preparation
US4662420A (en) * 1981-10-05 1987-05-05 Sanwa Shutter Corporation Panel shutter mechanism
US4454106A (en) * 1982-06-07 1984-06-12 Gansow Otto A Use of metal chelate conjugated monoclonal antibodies
US5362476A (en) * 1984-10-18 1994-11-08 Board Of Regents, The University Of Texas System Alkyl phosphonate polyazamacrocyclic cheates for MRI
US4779930A (en) * 1987-09-17 1988-10-25 Rosen Steven B Infant head support for use with infant retaining devices
US5739294A (en) * 1991-12-10 1998-04-14 The Dow Chemical Company Bicyclopol yazamacrocyclophosphonic acid complexes for use as contrast agents
US5428139A (en) * 1991-12-10 1995-06-27 The Dow Chemical Company Bicyclopolyazamacrocyclophosphonic acid complexes for use as radiopharmaceuticals
US5714604A (en) * 1993-05-06 1998-02-03 The Dow Chemical Company Process for the preparation of azamacrocyclic or acyclic aminophosphonate ester derivatives
KR20000010533A (ko) * 1996-04-19 2000-02-15 텍사스 테크 유니버시티 시각적 조직 특이성 조영제로서의 형광 킬레이트
US6670456B2 (en) * 2001-02-28 2003-12-30 Dow Global Technologies Inc. Actinium-225 complexes and conjugates for targeted radiotherapy
US7338651B2 (en) * 2001-09-04 2008-03-04 Texas Tech University System Multi-use multimodal imaging chelates

Also Published As

Publication number Publication date
EP1438076A1 (de) 2004-07-21
US20030133872A1 (en) 2003-07-17
EP1438076B1 (de) 2006-06-14
DE60212424T2 (de) 2006-10-12
ATE329623T1 (de) 2006-07-15
WO2003035114A1 (en) 2003-05-01
JP2005507001A (ja) 2005-03-10

Similar Documents

Publication Publication Date Title
DK1183255T3 (da) Metalkomplekser af bicykliske polyaminosyrer, fremgangsmåde til fremstilling af disse og anvendelse af disse til medicinsk billeddiagnostik
ATE556706T1 (de) Fettalkohol-arzneimittel-konjugate
MY136095A (en) Use of human anti-ctla-4 antibodies for treatment of cancer
TR200100054T2 (tr) Paroksetin metansülfonat
PL373302A1 (en) Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer
NO20054988D0 (no) Preparater og metoder for behandling av cancer
TR199903331T2 (xx) Farnesil protein transferas engelleyicileri.
HK1050860A1 (en) Nordihydroguaiaretic derivatives for use in treatment of tumors
DE69925276D1 (de) Stoffe und zusammensetzungen für die verabreichung aktiver substanzen
GEP20032897B (en) Epothilone Derivatives
ATE339406T1 (de) Chinazoline verbindungen als heilmittel
FI972287A (fi) Uudenlaisia polysubstituoituja DTPA-johdoksia ja niiden metallikomplekseja, kyseisiä komplekseja sisältäviä farmaseuttisia aineita, niiden käyttö diagnosoinnissa ja terapiassa sekä menetelmiä kyseisten kompleksinmuodostajien ja kompleksien valmistamiseksi ja menetelmiä kyseisten.
WO2003087831A3 (en) Proteins involved in breast cancer
HK1030144A1 (en) Method for treatment of liver tumours and pharmaceutical compositions for use therein.
DE60136826D1 (de) Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs
ATE500830T1 (de) Behandlung von krebs beim menschen mit et743
DE60124387D1 (de) Synergistische kombination zur behandlung von kolorektalkarzinom
MXPA03008582A (es) Agentes y metodos para tratamiento de cancer.
ATE240303T1 (de) 1,2,4-triazol-3-thion verbindungen
IL141550A0 (en) Methods and compositions for the prevention or treatment of cancer
DK1189627T3 (da) Sammensætninger indeholdende opløselige former af HLA-G til behandling af inflammatoriske patologiske tilstande i huden
DE60212424D1 (de) Radiopharmazeutishes mittel zur behandlung von krebs im frühstadium
DE69832722D1 (de) L-threonat-eisen, pharmazeutische zusammensetzung und verwendung zur verbesserung und behandlung von anämie bei menschen
NO20024755D0 (no) Metode
MY150767A (en) Polyethylene glycol modifications of thymosin alpha 1

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee